Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan

被引:0
|
作者
Shibata, Yasushi [1 ]
Sato, Hiroshige [2 ]
Sato, Akiko [3 ]
Harada, Yoichi [4 ]
机构
[1] Univ Tsukuba, Mito Med Ctr, Dept Neurosurg, Mito 3100015, Japan
[2] Sato Clin Internal Med & Neurosurg, Dept Neurosurg, Moriya, 6750115, Japan
[3] Sato Clin Internal Med & Neurosurg, Dept Neurol, Moriya 3020117, Japan
[4] Mito Brain Heart Ctr, Dept Neurosurg, Mito 3100004, Japan
来源
NEUROLOGY INTERNATIONAL | 2024年 / 16卷 / 03期
关键词
migraine; triptan; lasmiditan; step care; CGRP;
D O I
10.3390/neurolint16030048
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The combined use of lasmiditan and triptan is unexplored in medical literature. This study aimed to investigate whether the intake of lasmiditan following triptan improves migraine pain. Following triptan intake, if headache relief was less than 50% at 1 h, patients took 50 mg of lasmiditan within 2 h of migraine onset. Patients recorded headache intensity and adverse events (AEs) caused by lasmiditan at 1, 2, and 4 h after the intake of an additional 50 mg of lasmiditan. A significant reduction in pain scale was observed post 50 mg lasmiditan intake (p < 0.001, t-test). Pain relief was reported for 32 migraine attacks (80%) at 1 h after additional lasmiditan intake. Although AEs were observed in 63% of the patients who took an additional lasmiditan, most were mild and resolved 1 h after lasmiditan intake. Our study revealed the significant headache relief provided by an additional lasmiditan for patients who did not achieve satisfactory results following initial triptan intake for treating migraine. The AEs associated with this treatment strategy were mild and lasted for a short time. This study suggested that the combination of triptan and lasmiditan is promising for the treatment of migraine and should be studied in a randomized placebo-controlled trial.
引用
收藏
页码:643 / 652
页数:10
相关论文
共 50 条
  • [31] Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1593): : 35 - 39
  • [32] Lasmiditan: an additional therapeutic option for the acute treatment of migraine
    Martinelli, Daniele
    Bitetto, Vito
    Tassorelli, Cristina
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (05) : 491 - 502
  • [33] Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks
    Tfelt-Hansen, Peer
    Jorgensen, Karsten
    Diener, Hans-Christoph
    CEPHALALGIA, 2022, 42 (01) : 82 - 85
  • [34] Triptan Discontinuation and Treatment Patterns Among Migraine Patients Initiating Triptan Treatment in a US Commercially Insured Population
    Marcus, Steven C.
    Shewale, Anand R.
    Silberstein, Stephen D.
    Lipton, Richard B.
    Young, William B.
    Viswanathan, Hema N.
    Doshi, Jalpa A.
    NEUROLOGY, 2019, 92 (15)
  • [35] Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks
    Demirkaya, S
    Vural, O
    Dora, B
    Topçuoglu, MA
    HEADACHE, 2001, 41 (02): : 171 - 177
  • [36] Efficacy of Parecoxib, Sumatriptan, and Rizatriptan in the Treatment of Acute Migraine Attacks
    Mueller, Thomas
    Lohse, Lutz
    CLINICAL NEUROPHARMACOLOGY, 2011, 34 (06) : 206 - 209
  • [37] The efficacy and tolerability of frovatriptan and dexketoprofen for the treatment of acute migraine attacks
    Allais, Gianni
    Rolando, Sara
    De Lorenzo, Cristina
    Benedetto, Chiara
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (08) : 867 - 877
  • [38] Topiramate prophylaxis and response to triptan treatment for acute migraine
    Becker, Werner J.
    Christie, Suzanne N.
    Ledoux, Stephane
    Binder, Carin
    HEADACHE, 2006, 46 (09): : 1424 - 1430
  • [39] The specific treatment of migraine: a story about one triptan
    Tabeeva, G. R.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2007, 107 (05) : 75 - 78
  • [40] Post-triptan era for the treatment of acute migraine
    Goadsby P.J.
    Current Pain and Headache Reports, 2004, 8 (5) : 393 - 398